dr megan carter glp 1 🧬 Upcoming ACLM Webinar: "GLP‑1s: Great Little Peptides — Clinical Use & Lifestyle Medicine Integration" 📅 Tuesday, April 28 Dr. Megan R. Carter -

Which probiotic supplements and drinks failed our tests and which ones passed CL's Top Picks among probiotic supplements by category, including probiotic supplements for treating constipation and diarrhea, preventing C

Look for a provider with experience in obesity medicine who offers comprehensive care not just a prescription

New Customer Offer: $150 off for Life Welcome to Wellmedr

Disclosures: Janet Johnston: Nothing to Disclose, Youssef Barbour: Nothing to Disclose, Lisa Townshend-Bulson: Gilead Sciences: Grant/Research Support, Kena Desai: Nothing to Disclose, Chriss Homan: Nothing to Disclose, Wileina Rhodes: Nothing to Disclose, Brian McMahon: Nothing to Disclose 749 QUANTITATIVE ANALYSIS AND INTEGRATION OF MACHINE LEARNING FOR BIOMARKER ASSESSMENTS AND THEIR ASSOCIATION WITH TREATMENT RESPONSE: INSIGHTS FROM THE ENLIVEN PHASE 2B TRIAL OF PEGOZAFERMIN Oliver Mansbach 1 Arun Sanyal 2 Rada Savic 3 Leo Tseng 1 Kemal Balic 1 Shibao Feng 1 Lillian Tsai 1 Mildred Gottwald 1 Maya Margalit 1 Germaine Agollah 1 Hank Mansbach 1 Quentin Anstee 4 , 1 89bio, 2 Virginia Commonwealth University, 3 UCSF School of Pharmacy, 4 Newcastle University, UK Background: Pegozafermin (PGZ) is a long-acting glycoPEGylated analog of fibroblast growth factor 21 (FGF21)